Can enoxaparin reduce thromboembolism related events after primary TKA in Asian patients?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 23683524.
- Also identified by DOI 10.1016/j.arth.2013.04.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to investigate the efficacy and safety of enoxaparin in preventing venous and arterial thromboembolism related events after primary total knee arthroplasty (TKA) in Asian patients. Four hundred twenty nine patients (621 TKAs) did not receive thromboprophylaxis after TKA and 907 patients (1,336 TKAs) received enoxaparin after the procedure. We assessed clinically significant venous and arterial thromboembolism related events and bleeding complications. Total thromboembolism related events occurred in 13 patients (3.03%) without thromboprophylaxis and 17 patients (1.87%) with enoxaparin (P = 0.183). Our study showed that the incidence of clinically significant thromboembolism related events after TKA was very low in Asian patients. Enoxaparin had no benefits in reducing thromboembolism related events in Asian patients.
Medical subject headings
- Arthritis
- Arthroplasty, Replacement, Knee
- Enoxaparin
- Fibrinolytic Agents
- Knee Joint
- Thromboembolism
Anatomy
- knee